Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of February 2026. The filing incorporates by reference a press release dated February 16, 2026 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. The filing was signed on February 17, 2026, by Annelies Denecker, Company Secretary.

Note: The input metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as "Galapagos NV."

Financial Metrics

The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.

Material Changes

The filing text does not provide details on material changes versus prior periods. The document serves primarily to incorporate a press release by reference without summarizing its specific content in the body of the Form 6-K.

Guidance, Outlook, and Risks

The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are contained within the attached Exhibit 99.1 (Press Release), the text of which is not included in the provided input.

Key Facts for Investor Verification

  • Verify the actual content of the press release dated February 16, 2026, referenced as Exhibit 99.1, as the Form 6-K body contains no operational or financial details.
  • Confirm the correct registrant name is Galapagos NV, despite metadata discrepancies suggesting Lakefront Biotherapeutics NV.
  • Review the incorporated Registration Statements on Form S-8 listed in the filing for historical context on equity plans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.